CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...